Recommendations have been added on hand exercise programmes for people (adults) with rheumatoid arthritis.
These are marked as [new 2015].
Where recommendations end , the evidence has not been reviewed since the original guideline.
August 2013: A clarification was made to recommendation 184.108.40.206 about urgent referral for people with suspected persistent synovitis of undetermined cause.
August 2010: NICE published 'Rheumatoid arthritis – drugs for treatment after failure of a TNF inhibitor', NICE technology appraisal guidance 195. This replaces NICE technology appraisal guidance 126 'Rheumatoid arthritis (refractory) – rituximab' and NICE technology appraisal guidance 141 'Rheumatoid arthritis (refractory) – abatacept'. Please see NICE technology appraisal guidance 195 Rheumatoid arthritis – drugs for treatment after failure of a TNF inhibitor for the updated recommendations.
April 2009: A correction was made to the guideline. Recommendation 220.127.116.11 has been amended to remove text that stated an incorrect dose of etoricoxib for people with rheumatoid arthritis. The recommendation now reads: When offering treatment with an oral NSAID/COX-2 inhibitor, the first choice should be either a standard NSAID or a COX-2 inhibitor. In either case, these should be co-prescribed with a proton pump inhibitor (PPI), choosing the one with the lowest acquisition cost.
Note that recommendations 18.104.22.168–22.214.171.124 are adapted from the NICE guideline on osteoarthritis (CG59). These recommendations form part of the rheumatoid arthritis clinical guideline update of the rheumatoid arthritis aspects of TA27 Osteoarthritis and rheumatoid arthritis – cox II inhibitors.